InnoPharmax Inc. (TPEX:4172)
Taiwan · Delayed Price · Currency is TWD 11.15
-0.30 (-2.62%)
Aug 19, 2026, 1:52 PM CST
InnoPharmax Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 67.47 | 68.99 | 32.3 | 46.07 | 29.13 | 48.06 | |
Revenue Growth | 20.97% | 113.60% | -29.90% | 58.15% | -39.38% | -64.89% |
Cost of Revenue | 54.25 | 59.16 | 11.53 | 28.62 | 29.51 | 40.65 |
Gross Profit | 13.22 | 9.83 | 20.76 | 17.46 | -0.38 | 7.41 |
Selling, General & Admin | 27.14 | 26.36 | 21.43 | 22.97 | 21.51 | 22.43 |
Research & Development | 180.99 | 155.24 | 89.22 | 59.33 | 71.94 | 60.2 |
Operating Expenses | 206.05 | 181.59 | 116.74 | 82.3 | 92.95 | 81.79 |
Operating Income | -192.83 | -171.76 | -95.98 | -64.84 | -93.33 | -74.37 |
Interest Expense | -0.34 | -0.38 | -0.31 | -0.37 | -0.26 | -0.4 |
Interest & Investment Income | 2.47 | 2.84 | 1.92 | 1.64 | 0.98 | 1.01 |
Earnings From Equity Investments | -10.54 | -10.24 | -8.12 | -9.3 | -5.82 | -15.32 |
Currency Exchange Gain (Loss) | -0.94 | -0.94 | 0.4 | -0.07 | -0.13 | -0.79 |
Other Non Operating Income (Expenses) | 2.12 | -0.33 | 5.12 | 3.5 | -4.6 | 0.06 |
EBT Excluding Unusual Items | -200.07 | -180.82 | -96.97 | -69.43 | -103.15 | -89.81 |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.03 | - |
Asset Writedown | -0.08 | -0.08 | - | -1.4 | - | -3.16 |
Pretax Income | -200.14 | -180.89 | -96.97 | -70.83 | -103.18 | -92.97 |
Income Tax Expense | 3.51 | 3.51 | 2.32 | - | - | - |
Net Income | -203.65 | -184.4 | -99.29 | -70.83 | -103.18 | -92.97 |
Net Income to Common | -203.65 | -184.4 | -99.29 | -70.83 | -103.18 | -92.97 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 112 | 108 | 97 | 92 | 87 | 86 |
Shares Outstanding (Diluted) | 112 | 108 | 97 | 92 | 87 | 86 |
Shares Change | 8.37% | 10.36% | 5.83% | 6.20% | 0.31% | 12.92% |
EPS (Basic) | -1.82 | -1.71 | -1.02 | -0.77 | -1.19 | -1.08 |
EPS (Diluted) | -1.82 | -1.71 | -1.02 | -0.77 | -1.19 | -1.08 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -151.06 | -134.47 | -76.75 | -48.97 | -100.08 | -51.48 |
Free Cash Flow Per Share | -1.35 | -1.25 | -0.79 | -0.53 | -1.15 | -0.60 |
Gross Margin | 19.60% | 14.25% | 64.29% | 37.89% | -1.29% | 15.43% |
Operating Margin | -285.80% | -248.98% | -297.18% | -140.73% | -320.35% | -154.76% |
Profit Margin | -301.84% | -267.29% | -307.43% | -153.74% | -354.17% | -193.44% |
Free Cash Flow Margin | -223.90% | -194.92% | -237.64% | -106.29% | -343.51% | -107.11% |
EBITDA | -191.16 | -169.97 | -93.92 | -62.12 | -89.41 | -69.33 |
EBITDA Margin | -283.33% | -246.38% | -290.81% | -134.83% | - | -144.25% |
D&A For EBITDA | 1.67 | 1.79 | 2.06 | 2.72 | 3.92 | 5.05 |
EBIT | -192.83 | -171.76 | -95.98 | -64.84 | -93.33 | -74.37 |
EBIT Margin | -285.80% | -248.98% | -297.18% | -140.73% | - | -154.76% |